Genetic analysis and clinical features of X-linked retinoschisis in Chinese patients

被引:18
作者
Hu, Qin-Rui [1 ]
Huang, Lv-Zhen [1 ]
Chen, Xiao-Li [1 ]
Xia, Hui-Ka [1 ]
Li, Tian-Qi [1 ]
Li, Xiao-Xin [1 ]
机构
[1] Peking Univ Peoples Hosp, Dept Ophthalmol, Minist Educ, Key Lab Vision Loss & Restorat, Xizhimen South Street 11, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
JUVENILE RETINOSCHISIS; MUTATIONS; FAMILIES; RETINOPATHY; THERAPY; MOUSE; DORZOLAMIDE;
D O I
10.1038/srep44060
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Many mutations in the retinoschisis (RS1) gene have been identified, but there are limited clinical data relating to the different genotypes. This study investigated the genotype, clinical phenotype and therapies for X-linked juvenile retinoschisis (XLRS) patients in China to evaluate the effects of gene mutations and therapies on the prognosis of the disease. Thirty patients were recruited in the study. Genetic examination identified 8 novel RS1 gene mutations. Twenty-four patients were identified as missense mutation, which was the most common gene mutation in XLRS patients. Amino acids 102 and 209 were the most common mutation areas, accounting for a total 35.7% of all patients. Mutations affecting amino acid 102 were associated with poor results on the flash electroretinogram (ERG). Sixteen patients had various complications. Anti-vascular endothelial growth factor (VEGF) drugs were given to four patients with hemorrhage or other complications, and serious adverse events did not occur. Our outcome demonstrates that missense mutation was the leading cause of XLRS and more than half of the patients with this missense had various complications. Anti-VEGF drugs may be an effective and safe way to prevent deterioration of XLRS with certain complications. There is wide genotypic and phenotypic variability in Chinese patients with XLRS.
引用
收藏
页数:9
相关论文
共 31 条
[1]  
ALITALO T, 1988, AM J HUM GENET, V43, P476
[2]  
[Anonymous], 1898, ARCH AUGENHEILKD, V37, P343
[3]  
Bashar AE, 2016, MOL VIS, V22, P718
[4]  
BURNS R P, 1971, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V75, P1011
[5]  
Chen JQ, 2014, MOL VIS, V20, P132
[6]   INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT FOR RETINOPATHY OF PREMATURITY Comparison Between Ranibizumab and Bevacizumab [J].
Chen, San-Ni ;
Lian, Iebin ;
Hwang, Ya-Chi ;
Chen, Yi-Hsing ;
Chang, Yao-Chung ;
Lee, Kun-Hsien ;
Chuang, Chih-Chun ;
Wu, Wei-Chi .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2015, 35 (04) :667-674
[7]  
den Dunnen JT, 1998, HUM MOL GENET, V7, P1185
[8]  
FORSIUS H, 1973, CAN J OPHTHALMOL, V8, P385
[9]   Efficacy of Sustained Topical Dorzolamide Therapy for Cystic Macular Lesions in Patients With X-Linked Retinoschisis [J].
Genead, Mohamed A. ;
Fishman, Gerald A. ;
Walia, Saloni .
ARCHIVES OF OPHTHALMOLOGY, 2010, 128 (02) :190-197
[10]   INFANTILE PRESENTATION OF X-LINKED RETINOSCHISIS [J].
GEORGE, NDL ;
YATES, JRW ;
BRADSHAW, K ;
MOORE, AT .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1995, 79 (07) :653-657